



Annual Shareholders Meeting
October 2021

Rua Bioscience Limited (Rua) is a New Zealand pharmaceutical company aiming to be a leading producer of cannabinoid derived medicines. This presentation and the information contained in or accompanying this presentation are not, and are under no circumstances to be construed as, an invitation to subscribe for, or an offer of, shares, securities or financial products to any person, in any country or the basis for a contract, financial advice, other advice or recommendation to conclude any transaction for the purchase or sale of any security, loan or other instrument. This presentation has not been independently verified. Neither Rua nor any of its directors, officers, shareholders, advisors, agents or employees make any representation or warranty as to the accuracy or completeness of the information contained in this presentation and those parties shall have no liability for any statement, opinion, information or matters arising out of, contained in, or for any omissions from, or failure to correct or update any information in, this presentation or any other communications transmitted to you in relation to this presentation.

Company Overview and Chair's Address






Panapa Ehau
Ngāti Uepohatu, Ngāti
Porou
Director, Co-Founder

Manu Caddie
Ngāti Pūkenga, Ngāti Hauā
Kaihautu - Innovation and
Regulation, Co-Founder





Our vision at Rua Bioscience is simple – to create cannabinoid-derived medicines that change people’s lives; from right here in Te Tairāwhiti.

Te Rautaki o Rua

Our Strategy – Focus and Objectives



Creating Unique Product and Plant IP

- Create unique, sustainable and protected IP, cultivation techniques
- Develop commercially viable varieties of cultivars
- Use research partners to develop IP



Developing New Products and Markets

- Create new, protected product formulations
- Develop new, attractive markets
- Achieve sustainable revenue



Optimising Cultivation and Processing

- Achieve excellence in cultivation & processing techniques
- Develop cultivation partnerships to expand production
- Obtain licences and approvals for all processes, products, markets



Developing our People

- Build a capable and committed team
- Create employment pathways for Te Tairāwhiti residents

Te Paori Ringatohu Board of Directors

Trevor
Burt



Independent
Chairman
Heamana
Whakatū Pū
Wehe Kē

Appointed
August 2019.

Panapa
Ehau



Director,
Co-Founder
Kaiwhakaū /
Ringatohu
Ngāti
Uepohatu,
Ngāti Porou

Appointed
October 2017.

Brett
Gamble



Director
Ringatohu
Whakatū Pū
Wehe Kē

Appointed
December
2019.

Anna
Stove



Independent
Director
Ringatohu
Whakatū Pū
Pehe Kē

Appointed
May 2019.

Martin
Smith



Independent
Director
Ringatohu
Whakatū Pū
Pehe Kē

Appointed
Nov 2018.

Māwhiti mai ki ngā Whakatutukitanga

Achievements at a Glance



Successfully listed on NZX.



Built new facilities in Ruatorea and Tūranga /Gisborne.



Signed exclusive New Zealand supplier sales agreement with Nimbus Health in Germany.



Received commercial licence to grow and supply cannabis-derived medicines.



Exported first sample medicinal cannabis flower to Germany.

Māwhiti mai ki ngā Whakatutukitanga

Achievements at a Glance



Attracted key staff critical to the commercialisation of Rua operations.



Announced hyperspectral imaging project with the University of Waikato.



Developed the Rua Sustainability Framework.



Received commercial licence to grow and supply cannabis-derived medicines.




Received GMP Certification of our Gisborne manufacturing facility and first product.

Nga Kaipupuri Hea Our Shareholders

As at 30 June 2021:

- 2,901 shareholders
- 97.59% of our shareholders reside in New Zealand
- 37.23% reside in Te Tairāwhiti

GEOGRAPHICAL SPREAD OF OUR SHAREHOLDING AS AT 30 JUNE 2021



Nga Kaipupuri Hea

Our Shareholders

Top 10 Holders

1. Fang Group Investment Ltd
2. Hikurangi Bioactives Ltd Partnership
3. Tailorspace Capital Ltd
4. NZ Depository Nominee Ltd
5. Andrew Charles Williams
6. FNZ Custodians Ltd
7. Ridings Brothers Ltd
8. Custodial Services Ltd
9. Wakaroma A/C
10. Forsyth Barr Custodians Limited

Chief Executive Officer's Presentation





Hanga Wāriu
Creating Value

Good Manufacturing Practice (GMP) Certification

Globally recognised minimum standards for the manufacture of medicines.

Prerequisite for commercial production.

Key step on the path to revenue.

Rua began audit in November 2020 and achieved GMP certification of the Gisborne Manufacturing site on 28th September 2021.



Progress on Cultivation Optimization and Capacity

Well advanced in establishing our commercial cultivars.

Rua has signed three supply agreements with grower partners and an R&D supply agreement.

Trial started with the East Coast Cannabis Company on site in October 2021.



Research and Development

Rua announced a ground-breaking, two-year research programme to investigate the application of hyperspectral technology to the cultivation and assessment of medicinal cannabis, paving the way for Rua to enter New Zealand's booming agritech sector.



Ngā Pou Matua

Senior Management

Rob
Mitchell



Chief
Executive
Officer
Kaiwhakahāere
Matua

Manu
Caddie



Innovation and
Regulation,
Co-Founder
Kaiwhakaū /
Kaihautu

Ngāti Pūkenga,
Ngāti Hauā

Hamish
White



Chief Financial
Officer
Āpiha
Kaiwhakahāere
Pūtea

Ngāti Ruanui

Paul
Naske



Chief
Operations
Officer
Āpiha
Kaitohutihu
Matua

Dr Jessika
Nowak



Chief Research
Officer
Āpiha
Kairangahau
Matua

Dr Andrea
Grant



Chief
Commercial
Officer
Āpiha Kaihoko
Matua

Ngā Whakaurunga Āmua

Recruiting for the Future

Len Walker

Ngāti Porou, Aitanga-a-Hauti, Te Whānau-a-Apanui
Kaiwhakahāere hangahanga
Cultivation Manager
MBA

Len returns home having carved out an impressive management career in the Dairy industry that takes in Tui Co-operative Dairy Company, the NZ Dairy Research Institute, Edendale, Open Country Miraka, and Westland Milk Product.



Te Matapae o te Māketē o Aotearoa New Zealand Market Forecast


New Zealand is growing rapidly off a small base.

The number of packs of CBD products supplied in New Zealand in the year to 30 June 2021 was over 31,000.

This compares to just 2,000 in 2018.



CBD PRODUCTS SUPPLIED
PER ANNUM TO THE NZ
MARKET



Ngā mea Angitū o te Māketē ki Tiāmana

German Market Opportunities

Germany is currently the largest single market for GMP (pharmaceutical) grade cannabis globally.


Public health insurance coverage of prescriptions reached €90M in the first half of 2021.

With over €45M reimbursed in Q2 2021, it was a record quarter, increasing 2.5% over Q1 2021 and up 13% from Q2 2020.

184,499 cannabis prescriptions were covered by the public health system in H1 2021 (average of €487 per prescription).



MARKET SHARE OF
CANNABIS DRUGS IN
GERMANY




Graph Source: Prohibition Partners, 2021

Data Source: German National Association of Statutory Health Insurance Funds

Ngā mea Angitū o te Māketē o te Ao

Global Market Opportunities



CANNABIS LEGALISATION TO MARCH 2021


- Available via import*
- Production legalised
- Treatment legalised
- Medical and Recreational adult use legalised†

* In exceptional circumstances
† Includes countries with potential upcoming legalisation or upcoming pilot programme

Source: The Economist, 2021

Ārahitanga Whakahāere

Guidance on Timing



Opportunities

- Markets opening around the world
- Growing body of clinical evidence

Challenges

- Decades of stigma
- Meeting Minimum Quality Standards
- Expansion of foreign markets





Whai Hua mo Apōpō Towards Sustainability



Hamish Harris
Ngāti Porou, Nga Puhi
Plant Health Specialist

Whakapā atu ki te Iwi Whānui Community Engagement



Annual Results



Māwhiti mai ki ngā Hua Nui

Results at a Glance



Cash and
Investments

\$16.4M



Funds
Raised

\$20M



Other
Income

\$451K



Investment
in R&D

\$1.9M



Investment
in Property,
Plant and
Equipment

\$6.17M



Loss after
Tax

-\$4.42M

Māwhiti mai ki ngā Hua Nui

Results at a Glance – Profit and Loss



Loss after
Tax

-\$4.42M

Loss before tax	\$6.17M
Investment in R&D	\$1.90M
Other income	\$451K
Income Tax Credit	\$1.75M
Loss after tax	\$4.42M

Māwhiti mai ki ngā Hua Nui

Results at a Glance – Balance Sheet



Net Assets

\$28.8M

Cash & Investments	\$16.4M
Investment in property, plant and equipment	\$6.17M
Total assets	\$30.8M
Total liabilities	\$2M
Net assets	\$28.8M

Māwhiti mai ki ngā Hua Nui

Results at a Glance - Cashflow



Net Cash
Inflow

\$18.3M

Net cash outflow from operating activities

\$4.48M

Net cash outflow from investing activities

\$14.43M

Net cash inflow from financing activities

\$18.3M



IRUWA

B I O S C I E N C E

Nga mihi, e noho rā